Nimotuzumab
- Generic Name
- Nimotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
- Associated Therapies
- -
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Target Recruit Count
- 45
- Registration Number
- NCT06048913
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT06022276
- Locations
- 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 459
- Registration Number
- NCT05772208
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 288
- Registration Number
- NCT05717790
- Locations
- 🇨🇳
Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China
🇨🇳Guilin Medical University, China, Guilin, Guangxi, China
🇨🇳Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 42
- Registration Number
- NCT05316480
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05278728
- Locations
- 🇨🇳
China People's Liberation Army (PLA)81 Hospital, Nanjing, Jiangsu, China
🇨🇳Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China
Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Eye & ENT Hospital of Fudan University
- Target Recruit Count
- 95
- Registration Number
- NCT05024019
- Locations
- 🇨🇳
Ningbo Medical Center Lihuili Hospital, Ningbo, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Shanghai General Hospital/First People's Hospital Affiliated with Shanghai Jiao Tong University, Shanghai, China
Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT04976478
- Locations
- 🇨🇳
Peking University 3rd Hospital, Beijing, Beijing, China
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1931
- Registration Number
- NCT04949503
- Locations
- 🇨🇳
First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shannxi, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2021-05-12
- Target Recruit Count
- 100
- Registration Number
- NCT04882462
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.